AMBER ARMSTRONG: Open Payments
NPI 1225527344 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$7,271 in 203 payments from 20 companies in 2025. Trend: 2023 $844 · 2024 $4,566 · 2025 $7,271
Food & beverage: $4,293Consulting: $2,970Travel & lodging: $8
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 16 | $3,451 |
| ABBVIE INC. | 42 | $1,025 |
| PFIZER INC. | 24 | $477 |
| Celltrion USA Inc. | 23 | $365 |
| Janssen Biotech, Inc. | 14 | $300 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 19 | $263 |
| GENZYME CORPORATION | 7 | $199 |
| Aimmune Therapeutics, Inc. | 23 | $190 |
| Medtronic, Inc. | 2 | $152 |
| Ipsen Biopharmaceuticals, Inc | 5 | $147 |
Products named: VELSIPITY, TREMFYA, VEGZELMA, DUPIXENT, MAVYRET, XIFAXAN, ZENPEP, REZDIFFRA.
Industry payments across TX — which companies pay providers there.
